NEW YORK (GenomeWeb News) – AXA Diagnostics will distribute Rosetta Genomics' microRNA-based miRview line of molecular diagnostic cancer tests in Italy, Rosetta said today.

The exclusive distribution agreement with the Pomezia, Italy-based AXA Diagnostics covers the miRview mets, miRview squamous, and miRview meso tests. AXA will market the tests in Italy, and the samples will be analyzed at Rosetta Genomics' CLIA-certified lab in Philadelphia.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.

Sponsored by

This webinar describes a study that used two independent next-generation sequencing (NGS) platforms to gain insight into the impact of different types of aneuploidies during preimplantation genetic testing.

Sponsored by

This webinar will discuss the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.